Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about XCUR, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Cavrotolimod (AST-008) | Advanced or Metastatic Merkel Cell Carcinoma | Phase 1/2 · NCT03684785 | Terminated |
Also used in these trials (approved or third-party drugs, not XCUR's own candidates): Cemiplimab, Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
XCUR holds $1.7M in cash and short-term investments (as of Jun 30, 2026) and burns about $1M/quarter from operations, an estimated runway of 5.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 55 · Elevated
As a result, there is substantial doubt about our ability to continue as a going concern.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when XCUR files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| HiTron Systems Inc. | 5%+ holder (13D) | 3,333,333 | 50.92% | 2024-12-26 |
| Exicure HiTron Inc. 10% owner |
Insider | 2,222,224 | 33.95% | 2026-07-08 |
| DGP Co., Ltd. 10% owner |
Insider | 849,223 | 12.97% | 2024-09-12 |
| Andy Yoo Chief Restructuring Officer, Director |
Insider | 73,666 | 1.13% | 2024-11-21 |
| Josh Miller Chief Accounting Officer |
Insider | 301 | 0.00% | 2026-02-16 |
Share count 6,545,995 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for XCUR and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →